Evidence map›Paper›PMID 40046011›Full record

ArticleBioactive materials2025

Iterative selection of lipid nanoparticle vaccine adjuvants for rapid elicitation of tumoricidal CD8⁺ T cells.

Yuan Luo, Shiqi Zhou, Yiting Song, Wei-Chiao Huang, Gregory E Wilding, James Jablonski, Breandan Quinn, Jonathan F Lovell

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioactive materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuan LuoDepartment of Biomedical Engineering, State University of New York (SUNY) at Buffalo, Buffalo, NY, 14260, USA.
Shiqi ZhouDepartment of Biomedical Engineering, State University of New York (SUNY) at Buffalo, Buffalo, NY, 14260, USA.
Yiting SongDepartment of Biomedical Engineering, State University of New York (SUNY) at Buffalo, Buffalo, NY, 14260, USA.
Wei-Chiao HuangDepartment of Biomedical Engineering, State University of New York (SUNY) at Buffalo, Buffalo, NY, 14260, USA.
Gregory E WildingDepartment of Biostatistics, SUNY at Buffalo, Buffalo, NY, 14214, USA.
James JablonskiDepartment of Biomedical Engineering, State University of New York (SUNY) at Buffalo, Buffalo, NY, 14260, USA.
Breandan QuinnDepartment of Biomedical Engineering, State University of New York (SUNY) at Buffalo, Buffalo, NY, 14260, USA.
Jonathan F LovellDepartment of Biomedical Engineering, State University of New York (SUNY) at Buffalo, Buffalo, NY, 14260, USA.

Funding

A Cobalt Porphyrin Nanoliposome Adjuvant for MHC-I-Restricted Cancer Peptide VaccinesR01CA247771 · NCI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI ABRAMS, SCOTT I., LOVELL, JONATHAN F · 2020 to 2024
$1.9M
NCI NIH HHS R01 CA247771
6 · The paper itself

Abstract

A challenge for cancer vaccines is to elicit immune responses of sufficient magnitude to control malignant tumor growth and spread. In this study, we iteratively screened a panel of 22 lipid-phase vaccine adjuvants in mice for the elicitation of neoantigen-specific CD8⁺ T cell responses, using an integrated peptide-lipid nanoparticle approach. CL401, a dual Toll-like receptor 2/7 (TLR2/7) adjuvant rapidly induced neoantigen-specific T cell responses and improved lymphatic drainage and uptake of the particle. Additional rounds of

Identifiers

PMID40046011
PMCPMC11880734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.